GRGary Rudnick

Gary Rudnick

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gary Rudnick has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The role of chloride ions in serotonin transport

    by Jiahui Huang, Annika Backer, Stacy Uchendu, Bethlehem Bekele, Chan Li, Qingyang Chen, Esam A. Orabi, Robyn Stix, Jasper D. Shide, Yuan-Wei Zhang, et al.

    The human serotonin (5-HT + ) transporter SERT facilitates 5-HT + transport into cells by coupling it to Na + symport and K + antiport. Although extracellular Cl – is also essential for transport, Cl – cotransport has been disputed, raising questions about the role of Cl – ions and why they are required. We show that Cl – gradients do not impact 5-HT + accumulation, indicating that Cl – does not provide a driving force for uptake and arguing against stoichiometric Cl – symport. The presence of Cl – had only a small effect on Na + -mediated cytoplasmic pathway closure but markedly reduced the accessibility of residues in the extracellular pathway, consistent with modulation of the outward-facing states. Simulations illustrate that Cl – interacts strongly with a bound Na + ion and stabilizes helix packing on the extracellular side. We propose that Cl – acts as an essential architectural cofactor by enhancing Na + affinity and interactions between helices, thereby facilitating transport-related conformational transitions.

  • Open Access

    Role of Serotonin on Gene Expression and Physiology in Human Cytotrophoblasts and Placenta

    by Nolwenn S Morris, Seth Guller, Zhonghua Tang, Yuan-Wei Zhang, Erin C Siegman, Kristin M Milano, Gary Rudnick, Harvey J Kliman

    Serotonin (5-hydroxytryptamine; 5-HT) is transported into the human placenta through the serotonin transporter (SERT/SLC6A4) on the surface of the syncytiotrophoblast. During this transit, a significant amount of 5-HT becomes concentrated in the cytotrophoblast nucleus. We used immunochemistry, inhibitors of SERT and transglutaminase 2, and RNA sequencing to elucidate the mechanism and consequences of this nuclear localization. Exogenous 5-HT recapitulated the uptake of 5-HT into the trophoblasts and its preferential concentration in cytotrophoblast nuclei we observed in the intact placenta. Cystamine eliminated the staining of the nuclei in placental explants by exogenous 5-HT, suggesting that serotonylation mediated this phenomenon. This was confirmed by Western blots and immunoprecipitation that identified histone 3, and specifically the 5th glutamine residue in histone 3, as a site of serotonylation. Inhibiting SERT with escitalopram or transglutaminase 2 with cystamine blocked cytotrophoblast differentiation in vitro and led to marked changes in RNA expression. Of the 38 524 mRNAs identified in these trophoblasts, cystamine changed the expression of 1986 and escitalopram significantly altered 374. Both treatments altered the expression of 155 mRNAs either positively or negatively. The downregulated genes were involved with cell proliferation, morphogenesis, motility, and growth, whereas genes that were upregulated controlled cell survival and protection pathways. These findings suggest that maternal 5-HT promotes placental, embryonic/fetal, and organismal development through histone serotonylation and consequent alterations in gene expression. They raise the possibility that alterations in 5-HT flux in the placenta affect placental and fetal growth, as well as organismal somatic, neurologic developmental, and pathological trajectories.


  • Open Access

    The Role of Chloride Ions in Serotonin Transport

    by Jiahui Huang, Annika Backer, Stacy Uchendu, Bethlehem Bekele, Qingyang Chen, Esam Orabi, Robyn Stix, Yuan-Wei Zhang, Gary Rudnick, Eva Hellsberg, et al.

    The human serotonin (5-HT + ) transporter SERT facilitates 5-HT + transport into cells by coupling it to Na + symport and K + antiport. Although extracellular Cl − is also essential for transport, Cl − co-transport has been disputed, raising questions about the role of Cl − ions and why they are required. We show that Cl − gradients do not impact 5-HT + accumulation, indicating that Cl⁻ does not provide a driving force for uptake and arguing against stoichiometric Cl⁻ symport. The presence of Cl − had only a small effect on Na + -mediated cytoplasmic pathway closure but markedly reduced the accessibility of residues in the extracellular pathway, consistent with modulation of the outward-facing states. Simulations illustrate that Cl − interacts strongly with a bound Na + ion and stabilizes helix packing on the extracellular side. We propose that Cl⁻ acts as an essential architectural cofactor by enhancing Na + affinity and interactions between helices, thereby facilitating transport-related conformational transitions. Significance statement: The serotonin transporter (SERT) clears serotonin from synapses and is the target of widely used antidepressants. Although chloride ions are known to be required for SERT function, whether chloride is transported together with serotonin has remained unresolved for decades. We show that chloride gradients do not drive serotonin uptake, arguing against chloride symport. Instead, chloride stabilizes specific conformations of the transporter by strengthening sodium binding and extracellular helix packing. These findings redefine chloride not as a transported substrate, but as an architectural cofactor that facilitates conformational transitions required for transport. This reinterpretation reshapes our understanding of ion dependence in SERT and suggests a broader principle: ion requirements in related transporters may reflect structural stabilization rather than obligatory symport.

  • Open Access

    Identification of the potassium-binding site in serotonin transporter

    by Eva Hellsberg, Danila Boytsov, Qingyang Chen, Marco Niello, Michael Freissmuth, Gary Rudnick, Yuan-Wei Zhang, Walter Sandtner, Lucy R. Forrest

    Clearance of serotonin (5-hydroxytryptamine, 5-HT) from the synaptic cleft after neuronal signaling is mediated by serotonin transporter (SERT), which couples this process to the movement of a Na + ion down its chemical gradient. After release of 5-HT and Na + into the cytoplasm, the transporter faces a rate-limiting challenge of resetting its conformation to be primed again for 5-HT and Na + binding. Early studies of vesicles containing native SERT revealed that K + gradients can provide an additional driving force, via K + antiport. Moreover, under appropriate conditions, a H + ion can replace K + . Intracellular K + accelerates the resetting step. Structural studies of SERT have identified two binding sites for Na + ions, but the K + site remains enigmatic. Here, we show that K + antiport can drive substrate accumulation into vesicles containing SERT extracted from a heterologous expression system, allowing us to study the residues responsible for K + binding. To identify candidate binding residues, we examine many cation binding configurations using molecular dynamics simulations, predicting that K + binds to the so-called Na2 site. Site-directed mutagenesis of residues in this site can eliminate the ability of both K + and H + to drive 5-HT accumulation into vesicles and, in patch clamp recordings, prevent the acceleration of turnover rates and the formation of a channel-like state by K + or H + . In conclusion, the Na2 site plays a pivotal role in orchestrating the sequential binding of Na + and then K + (or H + ) ions to facilitate 5-HT uptake in SERT.


  • Open Access

    Identification of the potassium binding site in serotonin transporter SERT

    by Eva Hellsberg, Danila Boytsov, Qingyang Chen, Marco Niello, Michael Freissmuth, Gary Rudnick, Yuan-Wei Zhang, Walter Sandtner, Lucy Rachel Forrest

    Clearance of serotonin (5-hydroxytryptamine, 5-HT) from the synaptic cleft after neuronal signaling is mediated by serotonin transporter SERT, which couples this process to the movement of a Na + ion down its chemical gradient. After release of 5-HT and Na + into the cytoplasm, the transporter faces a rate-limiting challenge of resetting its conformation to be primed again for 5-HT and Na + binding. Early studies of vesicles containing native SERT revealed that K + gradients can provide an additional driving force, via K + antiport. Moreover, under appropriate conditions, a H + ion can replace K + . Intracellular K + accelerates the resetting step. Structural studies of SERT have identified two binding sites for Na + ions, but the K + site remains enigmatic. Here, we show that K + antiport can drive substrate accumulation into vesicles containing SERT extracted from a heterologous expression system, allowing us to study the residues responsible for K + binding. To identify candidate binding residues, we examine many cation binding configurations using molecular dynamics simulations, predicting that K + binds to the so-called Na 2+ site. Site directed mutagenesis of residues in this site can eliminate the ability of both K + and H + to drive 5-HT accumulation into vesicles and, in patch clamp recordings, prevent the acceleration of turnover rates and the formation of a channel-like state by K + or H + . In conclusion, the Na 2+ site plays a pivotal role in orchestrating the sequential binding of Na + and then K + (or H + ) ions to facilitate 5-HT uptake in SERT.


  • Faculty Opinions recommendation of The dopamine transporter antiports potassium to increase the uptake of dopamine.

    by Gary Rudnick

    This paper proposes that the dopamine transporter, an important target for drugs of abuse such as cocaine and methamphetamine, operates as an antiporter for potassium ions, coupling the efflux of K+ ions to the influx of dopamine. Dopamine transporter (DAT) also requires extracellular Na+ and Cl- ions for dopamine transport, like most mammalian transporters in the SLC6 family {1}, to which DAT belongs. Na+ and Cl- may be symported with dopamine, as has been shown for other transporters in this family such as glycine and GABA transporters (GlyT1,2 and GAT1) {2,3}. However, it has been difficult thus far to determine ion coupling stoichiometry for DAT because of confounding leak currents for these ions in DAT expression systems, along with evidence that DAT itself carries ionic currents that are uncoupled to transport. Schmidt et al. {4} have now attempted to circumvent ionic leaks by purifying and reconstituting DAT into proteoliposomes, removing leaks present in the membranes of their cellular expression system. Unfortunately, this procedure cannot eliminate uncoupled ionic leaks due to DAT itself. However, the paper shows conclusively that K+ interacts with DAT in ways that are consistent with dopamine/K+ antiport. These data include measurements of Na+-dependent ligand binding, and its inhibition by K+, by hydrogen-deuterium exchange measurements showing the conformational consequences of K+ binding. Most relevant to the question of dopamine/K+ antiport, however, are the experiments in reconstituted vesicles measuring fluxes of Na+, K+ and dopamine. The paper documents fluxes of both Na+ and K+ in DAT proteoliposomes preloaded with K+ and diluted into Na+ medium. The fluxes were blocked by a DAT inhibitor and stimulated by external dopamine. These measurements are difficult to make, and the authors should be commended on the technical advances required. The paper also shows proteoliposome experiments, in which dopamine uptake was apparently accumulated to a higher level when internal K+ was present. On the surface, these experiments would seem to validate the proposal of dopamine/K+ antiport. However, accumulation of a substrate inside a cell or vesicle requires a demonstration that the internal concentration is higher than in the external medium. The uptake is presented as “% of maximum”, which thwarts any conclusion that internal dopamine concentrations exceed those outside or even that the number of dopamine molecules transported exceed the number of DAT molecules in the membrane. Even if dopamine accumulated to a higher concentration inside, that stimulation by internal K+ could result from a K+ diffusion potential and not antiport. The closely related serotonin transporter (SERT) and excitatory amino acid transporters in the SLC1 family have been demonstrated to antiport internal K+ for external substrate {5,6}. However, uncoupled ion leaks catalyzed by DAT have presented a barrier to establishing the same phenomenon in DAT. Indeed, another recent attempt to evaluate the role of K+ in DAT also found interactions of K+ with the transporter but concluded that K+ antiport did not occur {7}.

  • Faculty Opinions recommendation of Cryo-EM structure of GABA transporter 1 reveals substrate recognition and transport mechanism.

    by Gary Rudnick

    This paper by Nayak et al. {1} extends structural analysis of one of the best studied neurotransmitter transporters. The GABA transporter GAT1 was the first neurotransmitter transporter cloned in the early 1990s {2}. Despite having been reconstituted {3} and purified {4} even earlier, inferences into its structure were based, until recently {5}, on the structures of related transporters such as LeuT, DAT, SERT and GlyT1, which transport neutral amino acids, dopamine, serotonin and glycine, respectively {6-9}. Of all these transporters, belonging to the NSS (or SLC6) family, only GAT1 transports an γ-amino acid, a feature it shares with the related transporters GAT2, GAT3 and BGT. The structure presented in this paper differs from the previous GAT1 structure bound to the inhibitor tiagabine {5} as it is in complex with a GABA molecule that apparently remained bound during purification. In this structure, the transporter assumes an inward-open conformation, with its extracellular substrate permeation pathway closed. In this sense, the structure is similar to previous structures of LeuT {10}, SERT {11} and GlyT1 {9}. However, those structures were obtained with a mutation or inhibitors that favored an inward-open conformation. This GAT1 structure is the first to show a substrate-bound inward-open state. Another paper {12} (also recommended {13}), which appeared together with this one, presents additional structures of GAT1, allowing additional insight into the structure and mechanism of this important neuronal protein. An excellent article {14} describing the structural differences highlighted by the two papers, appears in the same issue.

  • Faculty Opinions recommendation of Molecular basis for substrate recognition and transport of human GABA transporter GAT1.

    by Gary Rudnick

    This paper by Zhu et al. {1} further extends the structural analysis of the neuronal GABA transporter GAT1 that was presented in an accompanying paper {2} (also recommended {3}). While both papers present structures of GAT1 with GABA bound, the structure in this paper shows the transporter in an occluded conformation with both cytoplasmic and extracellular substrate permeation pathways closed while the GABA-bound structure in the other paper shows GAT1 in an inward-open conformation {2}. Although the reason for this difference is not understood, it is rare to see these conformations in a transporter of this NSS (or SLC6) family with substrate and Na+ bound. This paper also contains structures of GAT1 in the absence of organic ligands and in the presence of the related inhibitors tiagabine and nipecotic acid. The ligands have interesting effects on the conformation of GAT1. In the absence of ligands or in the presence of tiagabine, GAT1 was found in an inward-open conformation, as had been shown previously for tiagabine {4}. However, in the presence of the competitive substrate nipecotic acid, as with GABA, GAT1 was observed in an occluded conformation in which both pathways were closed. Previous structures of LeuT and MhsT, which are bacterial amino acid transporters belonging to the same NSS (or SLC6) family, were in a similarly occluded conformation {5,6}. Unlike GAT1, however, LeuT and SERT (an NSS transporter for serotonin) were in an outward facing form in the presence of Na+ and the absence of substrate {7,8}. It isn’t clear why LeuT and SERT prefer an outward-facing conformation in the absence of organic ligands while GAT1 prefers to be inward-facing, but the answer could relate to the influence of Na+. Na+ binds readily to LeuT and SERT, stabilizing an outward-open conformation. In GAT1, however, Na+ binding involves transmembrane charge movement and thus is facilitated by imposition of a membrane potential (inside negative) {9}. The propensity of GAT1 to assume an inward-open structure, as implied by the unliganded structure presented here, would require a conformational change prior to binding extracellular Na+ and this step could be responsible for the potential-dependence of Na+ binding to GAT1. An excellent article {10} describing the structural differences highlighted by the two papers, appears in the same issue as this paper.

  • Top Cited Papers

    Structure-based discovery of conformationally selective inhibitors of the serotonin transporter

    by Isha Singh, Anubha Seth, Christian B. Billesbølle, Joao Braz, Ramona M. Rodriguiz, Kasturi Roy, Bethlehem Bekele, Veronica Craik, Xi-Ping Huang, Danila Boytsov, et al.


  • Open Access

    Structure-based Discovery of Conformationally Selective Inhibitors of the Serotonin Transporter

    by Isha Singh, Anubha Seth, Christian B. Billesbølle, Joao Braz, Ramona M. Rodriguiz, Kasturi Roy, Bethlehem Bekele, Veronica Craik, Xi-Ping Huang, Danila Boytsov, et al.

    SUMMARY: The serotonin transporter (SERT) removes synaptic serotonin and is the target of anti-depressant drugs. SERT adopts three conformations: outward-open, occluded, and inward-open. All known inhibitors target the outward-open state except ibogaine, which has an unusual anti-depressant profile and stabilizes the inward-open conformation. Unfortunately, ibogaine is promiscuous and cardiotoxic, limiting understanding of inward-open state ligands. We computationally docked over 200 million small molecules against the ibogaine stabilized inward-open state of SERT. Thirty-six top-ranking compounds were synthesized and thirteen inhibited with potencies ranging from 29 to 5000 nM. Structure-based optimization led to two novel inhibitors with Ki values down to 3 nM. The new molecules stabilized an outward-closed state of the transporter and had little activity against off-targets. A cryo-EM structure of one of these bound to SERT confirmed the predicted geometry. In mouse behavioral assays, both had anxiolytic and anti-depressant activity, with potencies up to 200 better than fluoxetine.